These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21693737)

  • 1. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

  • 2. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Patti G; Pasceri V; Di Sciascio G
    JAMA; 2011 Jun; 305(24):2520-1; author reply 2521-2. PubMed ID: 21693736
    [No Abstract]   [Full Text] [Related]  

  • 3. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
    Gurbel PA; Tantry US; Shuldiner AR
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
    [No Abstract]   [Full Text] [Related]  

  • 5. Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel.
    Osnabrugge RL; Kappetein AP; Janssens AC
    JAMA; 2011 Feb; 305(5):467-8; author reply 468. PubMed ID: 21285422
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
    Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR;
    Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
    Price MJ; Berger PB; Teirstein PS; Tanguay JF; Angiolillo DJ; Spriggs D; Puri S; Robbins M; Garratt KN; Bertrand OF; Stillabower ME; Aragon JR; Kandzari DE; Stinis CT; Lee MS; Manoukian SV; Cannon CP; Schork NJ; Topol EJ;
    JAMA; 2011 Mar; 305(11):1097-105. PubMed ID: 21406646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
    Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
    Croce K
    Circ Cardiovasc Interv; 2010 Feb; 3(1):3-5. PubMed ID: 20160184
    [No Abstract]   [Full Text] [Related]  

  • 12. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
    JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
    Ramaraj R
    Lancet; 2009 Apr; 373(9670):1172; author reply 1172-3. PubMed ID: 19345827
    [No Abstract]   [Full Text] [Related]  

  • 14. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
    Kleiman NS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
    [No Abstract]   [Full Text] [Related]  

  • 15. Duration of clopidogrel therapy with drug-eluting stents.
    Rennings AJ; Schouwenberg BJ; van Onzenoort HA
    N Engl J Med; 2010 Jul; 363(5):489; author reply 490. PubMed ID: 20830829
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
    Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
    Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L
    Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
    Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
    J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.